Rephonic
Artwork for Not So Different: A Podcast from The Center for Biosimilars

Not So Different: A Podcast from The Center for Biosimilars

Not So Different: a Podcast from The Center for Biosimilars
Biosimilars
FDA
Healthcare Costs
Oncology
Cancer
Payer Decisions
Patient Access
Osteoporosis
Clinical Trials
Economic Barriers
Patient Outcomes
Healthcare Equity
U.S. Market Landscape
Pharmaceutical Industry
Clinical Evidence
Rheumatology
Denosumab
Ema
Economic Considerations
Regulatory Environment

"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.

PublishesMonthlyEpisodes157Founded8 years ago
Category
Health & Fitness

Listen to this Podcast

Artwork for Not So Different: A Podcast from The Center for Biosimilars

Latest Episodes

This special vodcast series provided by The Center for Biosimilars® was developed in partnership with the AAM and Biosimilars Council. Check out part 1 of the series featuring a discussion between Giuseppe Randazzo and Craig Burton, former executive ... more

Co-hosts Craig Burton, executive director of the Biosimilars Council, and Giuseppe Randazzo, senior vice president of sciences and regulatory affairs at the Association for Accessible Medicines (AAM), tackle the current biosimilar landscape and how t... more

Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that? Josh Canavan, head of pharmacy at RazorMetrics... more

In today’s episode, we dive into the FTC’s second interim report on PBMs, exposing key issues like preferential reimbursement for affiliated pharmacies. The findings raise questions about drug pricing transparency and PBM accountability. Joining us i... more

Key Facts

Accepts Guests
Contact Information
Podcast Host

Similar Podcasts

People also subscribe to these shows.

Recent Guests

Josh Canavan
Head of Pharmacy at RazorMetrics
RazorMetrics
Episode: S7 Ep3: How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
Joe Wisniewski
An expert in PBM legislation, price transparency, and healthcare policy.
Turquoise Health
Episode: S7 Ep2: Will the FTC Be More PBM-Friendly Under A Second Trump Administration?
Colin C. Edgerton, MD
A rheumatologist at Articularis Healthcare Group and member of the American College of Rheumatology Ultrasound Task Force
Articularis Healthcare Group
Episode: S6 Ep41: The Top 5 Most-Listened to Podcasts of 2024
Jeffrey Curtis, MD
A professor rheumatologist and epidemiologist at the University of Alabama at Birmingham, former member of the FDA Arthritis Advisory Committee
University of Alabama at Birmingham
Episode: S6 Ep41: The Top 5 Most-Listened to Podcasts of 2024
Hakun Wong
An intellectual patent attorney, partner at Venable LLP
Venable LLP
Episode: S6 Ep41: The Top 5 Most-Listened to Podcasts of 2024
Dracy Poor
Director of Biosimilars at Cardinal Health
Cardinal Health
Episode: S6 Ep41: The Top 5 Most-Listened to Podcasts of 2024
Kyle Noonan
Value and Access Strategy Manager at Sancora
Sancora
Episode: S6 Ep41: The Top 5 Most-Listened to Podcasts of 2024
Julie Reed
Executive Director of the Biosimilars Forum
Biosimilars Forum
Episode: S6 Ep41: The Top 5 Most-Listened to Podcasts of 2024
Craig Burton
Executive Director of the Biosimilars Council and Senior Vice President of Policy and Strategic Alliances at the Association of Accessible Medicines
Biosimilars Council
Episode: S6 Ep39: Can Global Policies to Boost Biosimilar Adoption Work in the US?

Host

Skyler Jeremias
Host of the podcast and involved with The Center for Biosimilars.

Reviews

4.5 out of 5 stars from 10 ratings
  • Great content! Critically important topic.

    I have enjoyed this content. Biosimilars are critical to reducing cost and improving access to care for patients. This podcast offers multifaceted coverage and incite full commentary— a must for physicians, medical professionals, and others who prescribe or deal with biosimilars.

    Apple Podcasts
    5
    Rheumprov
    United States6 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Listeners appreciate the critical insights shared about biosimilars and their importance in improving treatment access and reducing costs for patients.
Feedback emphasizes the essential nature of the content for those in healthcare and related sectors, highlighting its relevance and educational value.
The discussions cover a multifaceted view of biosimilars, appealing to healthcare providers and policymakers seeking depth on emerging treatments.

Top Health & Fitness Podcasts

unPAUSED with Dr. Mary Claire Haver
unPAUSED with Dr. Mary Claire HaverAudacy | Mary Claire Haver, MD
Passion Struck with John R. Miles
Passion Struck with John R. MilesPassion Struck Network
We're Out of Time
We're Out of TimeRichard Taite
The Peter Attia Drive
The Peter Attia DrivePeter Attia, MD
What Your Therapist Thinks
What Your Therapist ThinksFelicia Keller Boyle & Kristie Plantinga
Huberman Lab
Huberman LabScicomm Media

Talking Points

Recent interactions between the hosts and their guests.

S6 Ep32: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
Q: What strategies can health care providers employ to ensure a smooth transition for patients, potentially switching from reference denosumab to a denosumab biosimilar?
Healthcare providers must consider logistics related to ordering and administering biosimilars and ensure proper education within the team about the switch, while also tracking patients to ensure they receive timely treatment.
S6 Ep32: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
Q: What do you perceive to be the most significant diagnosis and treatment gaps in osteoporosis management?
There is a need for better recognition of osteoporosis among various specialists, including rheumatologists and orthopedists. Primary care also plays a crucial role in prioritizing osteoporosis screening and management.
S7 Ep2: Will the FTC Be More PBM-Friendly Under A Second Trump Administration?
Q: How might PBMs adjust their business strategies in response to increased scrutiny from the general public?
They should learn from hospitals' experiences and prepare offensive and defensive strategies for pricing transparency.
S7 Ep2: Will the FTC Be More PBM-Friendly Under A Second Trump Administration?
Q: Considering the backlash from the first FTC report, how do you think the Big Three may respond to the second report?
They will likely issue statements questioning the data and continue to argue that the FTC report relies on incomplete information.
S7 Ep2: Will the FTC Be More PBM-Friendly Under A Second Trump Administration?
Q: How do you think the FTC's efforts to investigate PBM practices and their impact on drug prices will shift in the next few years under a new Trump administration?
The Trump administration could create a more PBM-friendly environment, but there will still be pressure for accountability from the American public.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About This Podcast

What is This Podcast about and what kind of topics does it cover?

Focusing on the dynamic and rapidly evolving field of biosimilars, there are robust discussions surrounding their impact on healthcare costs, market accessibility, and patient adherence to treatment. Listeners can expect insights from various healthcare professionals, including physicians, pharmacists, and industry experts, which creates a multifaceted perspective on biosimilars. Notably, the content often highlights the economic benefits of biosimilars, regulatory nuances, and patient-centered approaches to treatment, making it a valuable resource for stakeholders involved in healthcare decision-making and policy development.

Where can I find podcast stats for this podcast?

Rephonic provides a wide range of podcast stats for this podcast. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to this podcast and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does this podcast get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for this podcast, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for this podcast?

Rephonic provides comprehensive predictive audience data for this podcast, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does this podcast have?

To see how many followers or subscribers this podcast has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to this podcast?

These podcasts share a similar audience with this podcast:

1. The Readout Loud
2. NEJM This Week

How many episodes of this podcast are there?

this podcast launched 8 years ago and published 157 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact this podcast?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for this podcast?

Rephonic pulls ratings and reviews for this podcast from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for this podcast?

Rephonic provides full transcripts for episodes of this podcast. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on this podcast?

Recent guests on this podcast include:

1. Josh Canavan
2. Joe Wisniewski
3. Colin C. Edgerton, MD
4. Jeffrey Curtis, MD
5. Hakun Wong
6. Dracy Poor
7. Kyle Noonan
8. Julie Reed

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days